FOR TRANSPLANT

The First Comprehensive Digital Medication Adherence Program

Connect with us

A program designed to engage and support both patients & transplant teams.

emocha’s Digital Adherence Program remotely engages & supports transplant recipients: resulting in better quality of life, improved clinical metrics, and decreased hospital utilization.

Our Digital Medication Adherence Program

Program Opportunities & Value

Increase the number of transplants your center can perform and improve your ranking and revenue.

Because emocha can support high adherence post discharge, we enable centers to perform more complex transplants (from HCV+ patients). We also improve patient outcomes leading to higher SRTR rankings. Both of these outcomes increase the volume of transplants a center is able to perform in a year.

Decrease likelihood of graft failure post-transplant.

Patients with early declining adherence have rejection rates that are 250% higher than patients with stable adherence rates, and an estimated 20-35% of medium-term graft failures fail largely due to nonadherence. emocha supports patients at every dose of medication through short video check-ins, confirming that immunosuppressive regimens are taken correctly and at the proper timing intervals.

Amplify care coordination after discharge.

When transplant recipients are discharged, care teams must ensure that they have clarity on which medications should be taken and when — as dose timeliness is a critical aspect of immunosuppressive adherence. Daily check-ins close the loop on care coordination post-discharge, eliminating costly medication training and gaps in care, and helping patients form lasting adherence habits.

Protect a second chance at life for transplant recipients.

Transplant recipients, donors, and care teams all bear the burdens of non-adherence and its implications. emocha’s program helps mitigate poor clinical outcomes, thus better protecting the transplantation process for all involved stakeholders.

Ensure costly medication is taken post-transplant.

Given the investment that health plans put into their transplant members, medication adherence is critical. Yet a significant percentage of patients are non-adherent to their anti-rejection immunosuppressive regimens: 15% – 40% among liver; 15% to 22% among kidney; and 20% among heart.

Trusted by leading health institutions.

Learn more about implementing emocha for your transplant patients.

Contact the team